Medicines and QT Prolongation by Ryuji Kato et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
Medicines and QT Prolongation 
Ryuji Kato, Yoshio Ijiri and Kazuhiko Tanaka 
Osaka University of Pharmaceutical Sciences 
Japan 
1. Introduction 
Significant QT interval prolongation may induce severe polymorphic ventricular tachycardia 
called Torsade de Pointes (TdP). TdP is a type of ventricular tachycardia (VT) characterized by 
a twist of the QRS wave around the baseline. In some cases this leads to fatal ventricular 
fibrillation (VF), which is why it is of particular importance among cases of arrhythmia.  
QT prolongation causes TdP which may then induce fatal VF. Common causes of QT 
prolongation include idiosyncratic causes such as gene deficiency, drugs, and drug-drug 
interactions. There are many cases of QT prolongation caused by drugs used to treat non-
cardiac related conditions; these cases involve unintended, adverse ‘collateral’ effects. 
Consequently, most of the drug-related cases fall outside the scope of the doctor's area of 
speciality and/or expectations, which makes it difficult to take preventive and therapeutic 
measures. It is for this reason that it is important to identify drugs that are likely to cause QT 
prolongation. Here, we outline drug that may cause QT prolongation and drug-drug 
interaction induced QT prolongation that could cause serious arrhythmia. 
2. What is QT prolongation? 
QT interval defines the start of the Q wave and the end of the T wave in an 
electrocardiogram, representing the time between depolarization and repolarization of the 
ventricles. Its value is a measurement from phase 0 (upstroke), through phase 1 (spike) and 
phase 2 (plateau) to phase 3 (rapid repolarization) (Fig. 1). Phase 4 is a phase between action 
potentials. QRS represents the depolarization of the ventricle, reflecting the membrane 
potential range as the ventricular depolarization wave propagates from subendocardial to 
subepicardial. The T wave represents the potential differences of ventricular repolarization. 
Factors that cause QT interval prolongation include the prolongation of cardiac ventricular 
action potential duration (APD), and an increase in nonuniformity of repolarization.  
The QT interval shortens in tachycardia but prolongs in bradycardia. There is no significant 
difference based on gender, while there is a weak tendency for the QT interval to prolong in 
females as they age. It is necessary to distinguish between two types of bradycardia: the PP 
interval prolongation on the one hand, and the QT interval prolongation on the other. When 
comparing QT intervals under different pulse rates, it is standard practice to use the 
corrected QT interval using Bazett’s formula (QTc = QT/ RR ). Other formulae include 
Fredericia’s (QTc = QT/ 3 RR ) and Van de Water’s (QTc = QT−0.087×(RR-1000)) (Kato et al., 
2009). The Bazett QTc values are smaller than actual QT measurements as the RR 
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Fig. 1. The relation between electrocardiogram and monophasic action potential from 
ventricular muscle. 
interval prolongs in bradycardia, while in tachycardia they are larger. Here, we adopt the 
formula among those mentioned above that shows the lowest correlation between the QTc 
and the RR interval. Normally, QTc values remain constant during both rest and exercise. 
QT prolongation occurs when QTc values fluctuate to greater than 0.44 sec. When the QTc 
values are normal (constant), the QT interval should be shortened under exercise compared 
with resting. QT prolongation occurs when this balance was disrupted. Significant QT 
interval prolongation may induce a severe polymorphic ventricular tachycardia called 
Torsade de Pointes (TdP). TdP is a type of ventricular tachycardia (VT) characterized by a 
twist of the QRS wave around the baseline. The pulse rate can reach 150-300 beats per 
minute, leading to severe symptoms such as fainting. In some cases this leads to fatal 
ventricular fibrillation (VF), which is why it is of particular importance amongst cases of 
arrhythmia. QT prolongation causes TdP that may induce fatal VF, which is why it is 
important to distinguish PP interval prolongation from QT interval prolongation.  
3. What causes QT prolongation? 
Long QT syndrome (LQTS) is roughly classified into two types, namely hereditary and 
acquired LQTS. The former is known to be caused by a disparity between the left and right 
sympathetic nerve systems stemming from some genetic defect, or by defect in SCN5A (the 
Na+ channel encoding gene) (Lehnart et al., 2007) or hERG (the K+ channel encoding gene) 
(Lehnart et al., 2007). Risk factors for the latter include: 1. An electrolyte abnormality such as 
hypokalemia (outward K+ current decreases, with APD prolonging) and magnesium 
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deficiency (diuretics can also be a significant cause); 2. Bradycardia; 3. Hypothyroidism; 4. 
Myocardial infarction with abnormality of K+ channel; 5. Drugs, and interactions between 
them.  
Next, let us turn now to the electrophysiological mechanism of LQTS. There are a number of 
different kinds of membrane currents on myocardial cells that are involved with resting 
potential and action potential formation. Extracellular Na+ and Ca2+ concentration levels are 
higher than intracellular levels, and the Na+ current that moves inward (from outside to 
inside of the cell) forms the depolarization phase (fast channel) while the Ca2+ current forms 
the plateau phase (slow channel). On the other hand, K+ concentration levels outside the 
cell are lower than levels inside, and the repolarization phase involves the delayed outward 
rectifying K+ current as well as the time-independent inward-rectifying K+ current. When 
factors such as drugs are introduced and suppress these K+ currents, the QT interval 
prolongs as the prolongation of action potential duration. In the case of TdP accompanying 
the acquired LQTS, the triggered activity by early afterdepolarization (EAD) or delayed 
afterdepolarization (DAD) is presumed to play an important role with a possible re-entry 
involvement.  
EAD is an oscillatory potential that occurs in the vulnerable period at the end of the plateau 
phase when APD prolonged. Triggered activity is generated when EAD reaches the 
threshold potential and triggers a new action potential. Proposed causes of EAD include: 1. 
K+ conductance reduction (K+ channel blocking); 2. Na+ conductance increases (aconite 
poisoning, familial LQTS); 3. Ca2+ conductance increases (sympathetic nervous system 
excitation, catecholamine administered). DAD, on the other hand, is an oscillation in the 
membrane potential immediately after the myocardinal action potential, or oscillatory after 
potential. The DAD oscillation can get big enough to constitute triggered activity. One way 
to grasp the effects on EAD and DAD is to measure the monophasic action potential (MAP) 
of the myocardium. The MAP measurement makes it possible to examine the Na+, Ca2+ and 
K+ currents. MAP30 (MAP duration at 30% of repolarization) indicates the Ca2+-ion inward 
current. MAP90 (MAP duration at 90% of repolarization) indicates the K+-ion outward 
current. MAP triangulation (MAP90–30) indicates if Ca2+ channels or IKr channels are 
involved (Kato et al., 2009).  
In the case of arrhythmia from digitalis, Na+/ K+-ATPase inhibition increases intracellular 
Na+ which activates the Na+/ Ca2+ exchange mechanism. This in turn increases the 
intracellular Ca2+ concentration level, generating an inward current which makes the 
sarcoplasmic reticulum unstable. Ca2+ may then be released from the sarcoplasmic 
reticulum during phase 4 in the action potential, again causing depolarization leading to 
DAD. However, DAD from digitalis should follow a relatively mild development, as it is 
caused by the pumping function of Na+/K+-ATPase; it is unlikely to induce TdP that leads 
to VF. 
4. TdP’s clinical manifestations, outcome and treatment 
While a number of TdP cases go unnoticed with no recognizable clinical symptoms, there 
are also cases with clear manifestations. Initial symptoms include increased dizziness, 
palpitation, pain in the chest, and discomfort in the epigastric region and in the chest. These 
are attributable to the elimination of the P wave by VT; blood ejection from the heart is 
suspended and no palpable pulse is detected, although the heart is still beating. At this 
stage, it is possible to manage the situation by discontinuing or reducing medication if there 
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is any suspected drugs. Symptoms may worsen to include anacatesthesia, fainting, and 
convulsion before proceeding to VF that causes sudden death. It is necessary at this stage to 
discontinue medication immediately (if any) and arrange for an AED as well as for an 
ambulance. The patient needs to be admitted to an ICU or CCU for treatments such as 
electrolyte correction, defibrillation, lidocaine administration, and temporary pacing. 
5. Drugs that may cause QT prolongation 
Drugs that may cause QT prolongation include anti-arrhythmics, psychotropics, and anti-
biotics among others (Table 1).  
5.1 Anti-arrhythmic drugs 
The drugs that fall under Ia in the Vaughan Williams classification reduce action potential 
slew rate (dP/dt max), and prolong APD by Na+ channel inhibition (depolarization phase). 
It follows then that reducing dP/dt max prolongs APD, but there is a limitation on the 
overloading of Ca2+ from sustained depolarization. Abnormal Na+ channel activities are 
unlikely to cause TdP unless there is a deficiency of SCN5A. TdP tends to occur in K+ 
currents where the K+ channel is inhibited, which delays repolarization time, with the result 
that APD is prolonged; K+ channel inhibition can prolong ADP indefinitely. Under Ic, 
propafenone is also thought to be a factor because of its β-blockade function that causes 
bradycardia.  
Under III, amiodarone, sotalol and bretyrium can prolong APD mainly by inhibiting 
outward K+ current (depolarization phase). They also share β-blocking properties that lead 
to bradycardia and hence to TdP.  
Under IV, bepridil, which is classified as Ca antagonist, is thought to inhibit Na+ channel 
and outward K+ current, which causes APD prolongation and TdP.  
5.2 Psychotropic drugs 
QT prolongation and TdP can be caused by antipsychotic drugs (chlorpromazine, 
phenothiazine; haloperidol, butyrophenone), tricyclic antidepressants (amitriptyline) and 
tetracyclic antidepressants (maprotiline). The mechanism appears to involve a quinidine-
like effect, while a range of factors are also cited such as electrolyte imbalance, myocardial 
membrane enzyme disorder, myocardial tissue degeneration, and effects on autonomic 
nervous system, among others (Hunt et al., 1995). 
5.3 Peripheral anti-histamine drugs 
Antiallergic drugs with antihistaminic properties such as terfenadine and astemizole fall 
under this group. Terfenadine and astemizole are prodrugs whose metabolites have 
antihistaminic properties. Their parent compounds significantly inhibit K+ currents. There 
have been fatal cases involving astemizole overdose as well as terfenadine administration 
where ventricular arrhythmia accompanied QT prolongation. In the five years after going 
on sale, seven severe side-effect cases of arrhythmia involving terfenadine were recognized. 
In 1995, a ‘warning’ section was added and the instructions for use were revised. However, 
in the two years following that, ten potentially fatal side-effect cases surfaced that involved 
QT prolongation and ventricular arrhythmia. In 1997, ‘Urgent Safety Information’ was 
submitted to call for extra care for the use of the drug before its sale was suspended in 2001. 
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The sale of astemizole was suspended in 1999. The mechanism of QT prolongation by 
terfenadine is thought to involve prolongation of myocardial repolarization time via 
delayed outward K+ current inhibition; it appears that antihistaminic metabolites do not 
significantly inhibit the K+ channel (Valenzuela et al., 1997). QT prolongation or TdP caused 
by these drugs is due not to antihistaminic properties but to K+ current inhibition. At 
present, there have been no reports of QT prolongation involving ebastine though it has 
been known to block delayed rectifier K+ current, albeit to a significantly lesser degree when 
compared to terfenadine (Valenzuela et al., 1997; Ko et al., 1997). It is in this context that 
fexofenadine, a metabolite of terfenadine, was developed. Fexofenadine is presumed to be 
safe, but its structural similarity to terfenadine suggests a possible parallel effect. Ebastine 
and fexofenadine need further careful study. 
5.4 Gastrointestinal prokinetic agents 
Cisapride was withdrawn from the market after the claim was made that it caused diabetic 
QT prolongation. Cisapride causes APD prolongation in extracted myocardial cells of 
laboratory animals, and dose-dependent prolongation of monophasic action potential 
duration (MAPD) in anesthetized animals, leading to QT prolongation and TdP (Carlsson et 
al., 2007). Mosapride is another gastrointestinal prokinetic agent with a similar chemical 
structure to that of cisapride. Animal testing has shown that it does not affect APD or 
MAPD, and it does not induce abnormal ECG such as QT prolongation or TdP (Carlsson et 
al., 2007).  
It appears then that QT prolongation caused by this group of drugs is based not on the 
serotonin agonist property, which is the drug’s main effect, but rather on its inhibition of the 
K+ channel.  
5.5 Macrolide anti-biotics 
Erythromycin causes QT prolongation by inhibiting the delayed rectifier K+ current (Rubart 
et al., 1993; Daleau et al., 1995). When combined with terfenadine or cisapride (discussed 
above), erythromycin enhances QT prolongation by blocking drug-metabolizing enzymes.  
5.6 Anthracycline anti-cancer drugs 
Among anthracycline anti-cancer drugs, doxorubicin is known to cause myocardial damage. 
It appears to enhance the sensitivity of depolarization in phase 4 (Mitrius et al., 1990).  
5.7 Azole anti-fungal drugs 
Azole anti-fungal drugs such as fluconazole and voriconazole are also known to cause QT 
prolongation. They are metabolized by the drug-metabolizing enzyme CYP3A4 while 
simultaneously inhibiting it. QT prolongation is caused either by the increasing serum 
concentration of the drug itself, or by increasing the serum concentration of some other drug 
that would otherwise be metabolized by CYP3A4; the latter case may involve a drug such as 
erythromycin. This calls for extra care for combinatory use of these drugs. 
5.8 Sulfonylureas (SUs) and Glinides as Oral Anti-diabetic Drugs 
SU and glinide agents are known to inhibit ATP-dependent K+ channels. The similarity in 
mechanism is also increasingly evident between Class Ia anti-arrhythmic drugs and the 
hypoglycemic function of SUs and glinides (Kakei et al., 1993; Hayashi et al., 2004). SUs and 
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glinides can potentially induce QT prolongation when they affect the heart’s ATP-
dependent K+ channels.  
5.9 Sulfa drugs 
Like SUs, a pentamidine and ST mixture may cause QT prolongation and hypoglycemia. 
Considering that SUs are modified sulfa drugs, they belong to the same strain that may 
affect ATP-dependent K+ channels. 
5.10 New quinolones 
There have been cases of TdP from QT prolongation caused by sparfloxacin and 
moxifloxacin, both new quinolones. The mechanism appears to involve K+ channel 
inhibition. 
5.11 Molecular targeted cancer drugs 
There have been cases of QT prolongation or myocardial damage from sunitinib, 
bortezomib, sorafenib, lapatinib, and nilotinib, among others.  
5.12 Others 
A study has been done on probucol induced QT prolongation as a result of a change in 
catecholamine sensitivity, as well as K+ current inhibition (Hayashi et al., 2004). Further 
study and consideration is needed. Meanwhile, QT prolongation is also known to be caused 
by diuretics that cause hypokalemia and magnesium deficiency, by cimetidine the histamine 
H2 receptor antagonist, or even by contrast media. 
 
 
Table 1. Drugs that may cause QT prolongation. 
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6. Drug-drug interaction induced QT prolongation 
Drug interaction is an important factor for QT prolongation. Drug-drug interaction is 
divided into pharmacodynamic interaction and pharmacokinetic interaction.  
6.1 Pharmacodynamic Interaction 
Drugs that are likely to cause QT prolongation are shown in Table 1. Combining two or 
more reinforces medicinal action additively; doses should be reduced or avoided altogether.  
6.2 Pharmacokinetic Interaction 
This involves cases where drug metabolism inhibition increases serum concentration, 
resulting in QT prolongation. Erythromycin, azole anti-fungal drugs, and molecular 
targeted cancer drugs are metabolized by CYP3A4, a microsomic drug metabolizing enzyme 
(that does exist outside the liver). When the above mentioned drugs were combined with a 
drug metabolized by enzymes of the same molecular kind or with a CYP3A4 blocking drug, 
the serum concentration to increase compared with a single dose of the drug (Table 2). The 
former is known as competitive antagonism, the latter as non-competitive antagonism; it is 
the latter that causes a sharper increase in serum concentration.  
An abnormal terfenadine-induced ECG is thought to be the result of increasing serum 
concentrations of an parent compound, produced by the combined use of terfenadine and a 
CYP3A4-blocking drug from Table 2. Drug-drug interactions like that just described are 
why the drugs shown under Table 2 were contraindicated for combined use. An active 
carboxylic acid metabolite of terfenadine called fexofenadine went on the market. It is 
claimed that fexofenadine does not have the same cardiac related side effects that tefenadine 
has, however the structural similarity between the two is enough to warrant some caution. 
Ebastine metabolism is thought to involve CYP3A4, a microsomic enzyme, as well a another 
metabolizing enzyme. In theory, ebastine should be less likely to lead to TdP than 
terfenadine, though extra care must be taken when extrapolating data from clinical and non-
clinical testing. 
Grapefruit juice is known to inhibit CYP3A4, which means it can cause QT prolongation by 
increasing the serum concentration of erythromycin, azole anti-fungal drugs, and molecular 
targeted cancer drugs.  
 
 
Table 2. Drugs that are likely to cause QT prolongation by CYP3A4-blocking. 
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7. QT prolongation - what measures to take 
In the case of drug-induced QT prolongation, the crucial clinical concern is not the QT 
prolongation itself, but TdP or VF that may follow. It is important then to determine 
whether QT prolongation is just a simple case of bradycardia (PP interval prolongation), or 
bradycardia caused by the QT prolongation. The main and intended effect of anti-
arrhythmic drugs classified under Ia is QT prolongation. However, drugs intended for other 
parts of the body can also cause the same QT prolongation in the heart; this is their collateral 
effect. Under these circumstances it has been extremely difficult for doctors to recognize 
early symptoms, largely because it falls outside the physician’s area of specialty when the 
case involves drugs other than those described under section 5-1 (‘Anti-arrhythmic Drugs’). 
There was a case of antipruritic (anti-histamine agent) that caused a totally unexpected fatal 
arrhythmia. Cisapride disappeared from the market, leaving the new term ‘Diabetic QT 
Prolongation’. Furthermore, it is intriguing to note the similarity in mechanism between SUs 
and cibenzoline, an anti-arrhythmic drug classified under Ia of the Vaughan-Williams 
classification. Far too many QT prolongation cases that could have been predicted have 
gone unnoticed. The intended effect of the drug was the focus of attention, while the 
obvious ‘collateral effect’ was unobserved. 
In order to detect early symptoms of the collateral effect, attention must be paid to: 1. What 
drugs can cause a collateral effect; 2. Factors on the part of the patient (e.g. certain conditions 
obtained when sick); 3. Drug-drug interaction. When encountered with early symptoms of 
TdP such as increased dizziness, palpitation, pain in the chest, and discomfort in the 
epigastric region and in the chest, medication should be discontinued and immediate 
medical attention should be sought.  
8. Conclusion 
Side effects are classified into toxic (dose-dependent) and allergic. The former is a simple 
extension of the main effect: serum concentration increases dose-dependently in a 
predictable fashion. The latter is hard to predict because it increases dose-independently in 
an idiosyncratic fashion. The QT prolongation under discussion belongs to the former and is 
indeed predictable. When QT prolongation is an extension of the main drug effect (anti-
arrhythmic effect) and is confirmed by a specialist as such, preventive or therapeutic 
measures can be taken before it is too late. However, when QT prolongation is caused by 
the drugs discussed under sections 5-2 through 5-12 (psychotropics, anti-histamines, 
gastrointestinal prokinetic agents, anti-biotics, anti-cancer agents, etc.), it is difficult to take 
preventive or therapeutic measures against these ‘collateral’ effects because most of these 
cases are simply beyond the scope of the doctor in charge. This has indeed resulted in a 
number of cases where QT prolongation was not diagnosed, with unfortunate results. It is 
essential to learn from these past experiences and develop proactive treatments. 
A new guideline (ICH S7B) providing provisions for a QT prolongation screening test for 
new drug development was issued by ICH, the International conference on Harmonization 
of Technical Requirements for Registration of Pharmaceuticals for Human Use 
(http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html). Aside 
from the provided guidelines, it is important to look for substances that do not block K+ 
channels when developing drugs; one can make use of hERG or a screening method using 
MAP (Kato et al., 2009) . 
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